PRTA Long Call Strategy
PRTA (Prothena Corporation plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA (Prothena Corporation plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $502.6M, a beta of -0.23 versus the broader market, a 52-week range of 4.32-11.8, average daily share volume of 505K, a public-listing history dating back to 2012, approximately 163 full-time employees. These structural characteristics shape how PRTA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.23 indicates PRTA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on PRTA?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current PRTA snapshot
As of May 15, 2026, spot at $9.80, ATM IV 81.10%, IV rank 14.28%, expected move 23.25%. The long call on PRTA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on PRTA specifically: PRTA IV at 81.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a PRTA long call, with a market-implied 1-standard-deviation move of approximately 23.25% (roughly $2.28 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PRTA expiries trade a higher absolute premium for lower per-day decay. Position sizing on PRTA should anchor to the underlying notional of $9.80 per share and to the trader's directional view on PRTA stock.
PRTA long call setup
The PRTA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PRTA near $9.80, the first option leg uses a $9.80 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PRTA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PRTA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $9.80 | N/A |
PRTA long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
PRTA long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on PRTA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on PRTA
Long calls on PRTA express a bullish thesis with defined risk; traders use them ahead of PRTA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
PRTA thesis for this long call
The market-implied 1-standard-deviation range for PRTA extends from approximately $7.52 on the downside to $12.08 on the upside. A PRTA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current PRTA IV rank near 14.28% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PRTA at 81.10%. As a Healthcare name, PRTA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PRTA-specific events.
PRTA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PRTA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PRTA alongside the broader basket even when PRTA-specific fundamentals are unchanged. Long-premium structures like a long call on PRTA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PRTA chain quotes before placing a trade.
Frequently asked questions
- What is a long call on PRTA?
- A long call on PRTA is the long call strategy applied to PRTA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With PRTA stock trading near $9.80, the strikes shown on this page are snapped to the nearest listed PRTA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PRTA long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the PRTA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 81.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PRTA long call?
- The breakeven for the PRTA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PRTA market-implied 1-standard-deviation expected move is approximately 23.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on PRTA?
- Long calls on PRTA express a bullish thesis with defined risk; traders use them ahead of PRTA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current PRTA implied volatility affect this long call?
- PRTA ATM IV is at 81.10% with IV rank near 14.28%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.